Communiqués Bayer AG

Actions

BAYN

DE000BAY0017

Produits pharmaceutiques

Marché Fermé - 17:35:26 17/09/2026 Après clôture 21:59:59
49,04 EUR +0,12% Graphique intraday de Bayer AG 49,10 +0,13%

Communiqués

15:06 Robigo and Leaps by Bayer Announce Series A Financing to Advance Engineered Biologicals That Protect Yields and Reduce Costs BU
15:05 Bayer : Robigo and Leaps by Bayer Announce Series A Financing to Advance Engineered Biologicals That Protect Yields and Reduce Costs PU
08:35 Bayer : U.S. FDA approves finerenone for new indication in patients with chronic kidney disease associated with type 1 diabetes PU
08:30 Bayer’s KERENDIA® (finerenone) Receives FDA Approval as the First New Treatment in 30 Years for Adults with Chronic Kidney Disease (CKD) and Type 1 Diabetes BU
10/09 Bayer Launches Nationwide Science Delivers Tour to Take Science on the Road BU
10/09 U.S. FDA Grants Accelerated Approval to Bayer’s HYRNUO® (sevabertinib) as a First-Line Targeted Therapy for Patients with HER2-Mutated Non-Small Cell Lung Cancer BU
09/09 Bayer : U.S. FDA grants accelerated approval to Bayer’s targeted therapy sevabertinib as a first-line treatment option for adults with HER2-mutant non-small cell lung cancer PU
09/09 Bayer : and Neste close commercial agreement to jointly scale newgold® winter canola for biofuels production PU
09/09 BAYER INITIATES PHASE II STUDY OF INVESTIGATIONAL GIRK4 INHIBITOR IN PATIENTS WITH ATRIAL FIBRILLATION BU
09/09 Bayer : initiates Phase II study of investigational GIRK4 inhibitor in patients with atrial fibrillation PU
03/09 Bayer Advances Combined Seed and Crop Protection Pipeline and Enters Phase of Blockbuster Launches AQ
31/08 Bayer : Finerenone slowed kidney function decline and reduced kidney-cardiovascular risk versus placebo in patients with hypertensive nephropathy PU
30/08 Bayer Announces Phase III REVEAL Study with Investigational PET Radiotracer Iodine 124 Evuzamitide Presented as Late-Breaker at ESC 2026 BU
29/08 Bayer : AskBio Presents Baseline Characteristics from Phase 2 Heart Failure Gene Therapy Trial of Umiposgene Parvec (AB-1002) at European Society of Cardiology Congress PU
24/08 Bayer : sevabertinib approved in Japan for patients with HER2-mutant non-small cell lung cancer PU
20/08 Bayer to Present New Phase III Data from Its Cardiovascular, Kidney, and Stroke Clinical Trial Programs at ESC 2026 BU
17/08 LYNKUET® (élinzanétant) obtient une autorisation de mise en marché élargie au Canada pour le traitement des symptômes vasomoteurs modérés ou graves causés par un traitement endocrinien adjuvant du cancer du sein BU
13/08 Bayer : Aflibercept 8 mg application for macular edema following retinal vein occlusion accepted for review in China PU
04/08 Bayer : Q2 Media Update PU
04/08 Bayer : Second Quarter 2026 Results and Media Update PU
04/08 Bayer : operationally on track, decisive progress on strategic priorities PU
30/07 Bayer : submits application for next indication of Kerendia in China PU
28/07 One A Day® Introduces New Women's Multi Gummy Formula with 1,000 mcg Biotin BU
23/07 New Economist Enterprise Research Highlights Why Integrating Self-Care Into Health Systems Matters BU
23/07 Bayer : New Economist Enterprise research highlights why integrating self-care into health systems matters PU
Aucun résultat pour cette recherche
DERNIÈRES HEURES | -40% : Les Meilleurs Outils Réservés aux Abonnés pour Identifier les Meilleurs Investissements de Demain !
j
:
:
PROFITEZ-EN MAINTENANT